The xT CDx is a sophisticated genomic profiling platform designed to enhance personalized therapeutic opportunities for cancer patients. It integrates extensive molecular profiling with clinical data, optimizing targeted therapies and identifying potential clinical trials. This platform is superior in its ability to conduct paired tumor and normal sequencing, augmented by transcriptome sequencing, which surpasses tumor-only DNA panel tests in accuracy and comprehensiveness.
With its robust capabilities, the xT CDx enables the identification of actionable genetic variants that might be overlooked if only traditional solid tumor or liquid biopsy testing methods were employed. This comprehensive approach allows clinicians to make more informed treatment decisions, offering patients tailored therapeutic options and improving their clinical outcomes.
The system’s compatibility with various clinical settings is further underscored by its ease of integration into existing workflows, making it a versatile tool for medical professionals aiming to implement precision medicine in oncology practice efficiently.
